New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
16:22 EDTPDIIPDI, Inc. reports Q3 EPS (6c), consensus (4c)
Reports Q3 revenue $31.8M, consensus $34.76M.
News For PDII From The Last 14 Days
Check below for free stories on PDII the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2014
16:15 EDTPDIIPDI, Inc. still expects 2014 revenue to be down from 2013
The company said, "As for our outlook for the remainder of the year, we continue to expect revenue in our core business to be down in the third quarter and for the full year compared to 2013. We still anticipate an operating loss in the range of $4 - $5 million and approximately breakeven adjusted EBITDA in the core business for the full year 2014. Given today's Asuragen transaction, we now see a modest amount of revenues from Interpace Diagnostic for 2014 and an operating loss in the range of $5 - $6 million from all Interpace Diagnostics activities including additional selling and marketing and pre-launch expenses to support the anticipated ramp up of revenue from the acquired Asuragen assets."
16:14 EDTPDIIPDI, Inc. reports Q2 EPS (17c), consensus (12c)
Subscribe for More Information
16:08 EDTPDIIPDI, Inc. subsidiary acquires miRInform test assets from Asuragen
PDI, Inc. announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform Thyroid and Pancreas cancer test assets from privately held Asuragen. This acquisition marks the execution of PDI's strategy to create a commercially driven molecular diagnostics business and a commitment to developing new solutions for the thyroid and pancreatic cancer testing markets. This transaction includes the miRInform Thyroid and Pancreas tests, intellectual property related to these and other tests in development for thyroid cancer, and an extensive 5,000 plus tissue sample biobank to support life cycle management efforts. Terms of the transaction include $8M in upfront cash, future commercial milestone-based payments and royalties.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use